14290GS-US-595-6184-ASCENT-05OpenA Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab
Govitecan and Pembrolizumab Versus Treatment of Physician s Choice in
Patients With Triple Negative Breast Cancer Who Have Residual Invasive
Disease After Surgery and Neoadjuvant TherapyNCT05633654IndustrialAdultTreatmentIIIGlobalBreastChitalia, AmiMedStar Health and GUMC; Medstar Franklin Square Medical Center; Medstar Good Samaritan Hospital; Medstar Washington Hospital CenterBreastOncology GroupMHRI Washington Cancer Institute2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>